File card for Exelon makes unsubstantiated superiority claims

A professional file card for Novartis' Exelon makes unsubstantiated superiority claims, overstates the drug's efficacy, includes misleading risk presentations and recommends or suggests an unapproved use, says the FDA. It wants Novartis to submit a plan for circulating corrective materials.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions